MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy

Long-term tamoxifen treatment significantly improves the survival of hormone receptor-positive (HR+) breast cancer (BC) patients. However, tamoxifen resistance remains a challenge. We aimed to identify prognostic biomarkers for tamoxifen resistance and reveal the underlying mechanism. From March 200...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, XiaoRong, Xie, GuiQin, Zhang, Zhang, Wang, Zhu, Wang, Yu, Wang, YanPing, Qiu, Yan, Li, Li, Bu, Hong, Li, JiaYuan, Zheng, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308643/
https://www.ncbi.nlm.nih.gov/pubmed/27533459
http://dx.doi.org/10.18632/oncotarget.11278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308643/
https://www.ncbi.nlm.nih.gov/pubmed/27533459
http://dx.doi.org/10.18632/oncotarget.11278

Ejemplares similares